Abstract
Aims and background. The aim of this study was to evaluate the relationship between a panel of biological markers (p53, Bcl-2, HER-2, Ki67, DNA ploidy and S-phase fraction) and clinical-pathological parameters and its impact on outcome in non-small cell lung cancer (NSCLC). Methods and study design. Tumor tissue specimens obtained after surgical resection were collected from consecutive patients with NSCLC. We used an immunocyto-chemical technique for p53, Bcl-2, HER-2 and Ki67 analysis in fine-needle aspirates obtained from surgical samples that were also evaluated by flow cytometric DNA analysis using a FACScan flow cytometer. Results. From April 2000 to December 2005, 136 patients with radically resected NSCLC were recruited. Median age was 66 years (range, 31-84 years), male/female ratio 117/19, ECOG performance status 0/1 127/4, stage I/II/III 76/25/35, squamous/adenocarcinoma/large-cell/mixed histology 62/49/17/8, smokers yes/no 121/11. Positivity of p53, Bcl-2, HER-2 and Ki67 was detected in 51.4%, 27.9%, 25.0% and 55.8% of the samples, respectively; 82.9% of the cases revealed aneuploid DNA histograms and 56.7% presented an S-phase fraction of more than 12%. Statistically significant associations between high Ki67 and poorly differentiated tumors (P = 0.016) and a smoking history (P = 0.053); p53 positivity and high Ki67 (P = 0.002); HER-2 positivity and adenocarcinoma subtype (P = 0.015) and presence of lymph node involvement (P = 0.006); and Bcl-2 positivity and squamous cell carcinoma subtype (P= 0.058) were observed. At univariate analysis, high Ki67 proved to be the only marker associated with disease-free survival (P = 0.047). After adjusting for stage, none of the examined immunocytochemical markers emerged as an independent factor for disease-free and overall survival; only pathological stage was identified as an independent prognostic factor for disease-free survival (P = 0.0001) and overall survival (P = 0.0001). In the group of 76 patients classified as TNM stage I, high Ki67 was the only marker associated with recurrence of disease (P= 0.05). Conclusions. Our data do not support a relevant prognostic role of immunocyto-chemical markers in NSCLC, even if the Ki67 index might have particular relevance to identify patients with more aggressive tumors who are at high risk for disease relapse.
| Original language | English |
|---|---|
| Pages (from-to) | 398-405 |
| Number of pages | 8 |
| Journal | Tumori |
| Volume | 94 |
| Issue number | 3 |
| Publication status | Published - May 2008 |
Fingerprint
Keywords
- Bd-2
- DNA ploidy
- HER-2
- Ki67
- Non-small cell lung cancer
- p53
- Prognosis
- S-phase fraction
ASJC Scopus subject areas
- Cancer Research
Cite this
Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the perugia multidisciplinary team for thoracic tumors. / Ludovini, Vienna; Pistola, Lorenza; Gregorc, Vanesa; Floriani, Irene; Rulli, Eliana; Di Carlo, Luciana; Semeraro, Antonia; Daddi, Giuliano; Darwish, Samir; Stocchi, Lucia; Tofanetti, Francesca Romana; Bellezza, Guido; Sidoni, Angelo; Tognellini, Rita; Crinò, Lucio; Tonato, Maurizio.
In: Tumori, Vol. 94, No. 3, 05.2008, p. 398-405.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the perugia multidisciplinary team for thoracic tumors
AU - Ludovini, Vienna
AU - Pistola, Lorenza
AU - Gregorc, Vanesa
AU - Floriani, Irene
AU - Rulli, Eliana
AU - Di Carlo, Luciana
AU - Semeraro, Antonia
AU - Daddi, Giuliano
AU - Darwish, Samir
AU - Stocchi, Lucia
AU - Tofanetti, Francesca Romana
AU - Bellezza, Guido
AU - Sidoni, Angelo
AU - Tognellini, Rita
AU - Crinò, Lucio
AU - Tonato, Maurizio
PY - 2008/5
Y1 - 2008/5
N2 - Aims and background. The aim of this study was to evaluate the relationship between a panel of biological markers (p53, Bcl-2, HER-2, Ki67, DNA ploidy and S-phase fraction) and clinical-pathological parameters and its impact on outcome in non-small cell lung cancer (NSCLC). Methods and study design. Tumor tissue specimens obtained after surgical resection were collected from consecutive patients with NSCLC. We used an immunocyto-chemical technique for p53, Bcl-2, HER-2 and Ki67 analysis in fine-needle aspirates obtained from surgical samples that were also evaluated by flow cytometric DNA analysis using a FACScan flow cytometer. Results. From April 2000 to December 2005, 136 patients with radically resected NSCLC were recruited. Median age was 66 years (range, 31-84 years), male/female ratio 117/19, ECOG performance status 0/1 127/4, stage I/II/III 76/25/35, squamous/adenocarcinoma/large-cell/mixed histology 62/49/17/8, smokers yes/no 121/11. Positivity of p53, Bcl-2, HER-2 and Ki67 was detected in 51.4%, 27.9%, 25.0% and 55.8% of the samples, respectively; 82.9% of the cases revealed aneuploid DNA histograms and 56.7% presented an S-phase fraction of more than 12%. Statistically significant associations between high Ki67 and poorly differentiated tumors (P = 0.016) and a smoking history (P = 0.053); p53 positivity and high Ki67 (P = 0.002); HER-2 positivity and adenocarcinoma subtype (P = 0.015) and presence of lymph node involvement (P = 0.006); and Bcl-2 positivity and squamous cell carcinoma subtype (P= 0.058) were observed. At univariate analysis, high Ki67 proved to be the only marker associated with disease-free survival (P = 0.047). After adjusting for stage, none of the examined immunocytochemical markers emerged as an independent factor for disease-free and overall survival; only pathological stage was identified as an independent prognostic factor for disease-free survival (P = 0.0001) and overall survival (P = 0.0001). In the group of 76 patients classified as TNM stage I, high Ki67 was the only marker associated with recurrence of disease (P= 0.05). Conclusions. Our data do not support a relevant prognostic role of immunocyto-chemical markers in NSCLC, even if the Ki67 index might have particular relevance to identify patients with more aggressive tumors who are at high risk for disease relapse.
AB - Aims and background. The aim of this study was to evaluate the relationship between a panel of biological markers (p53, Bcl-2, HER-2, Ki67, DNA ploidy and S-phase fraction) and clinical-pathological parameters and its impact on outcome in non-small cell lung cancer (NSCLC). Methods and study design. Tumor tissue specimens obtained after surgical resection were collected from consecutive patients with NSCLC. We used an immunocyto-chemical technique for p53, Bcl-2, HER-2 and Ki67 analysis in fine-needle aspirates obtained from surgical samples that were also evaluated by flow cytometric DNA analysis using a FACScan flow cytometer. Results. From April 2000 to December 2005, 136 patients with radically resected NSCLC were recruited. Median age was 66 years (range, 31-84 years), male/female ratio 117/19, ECOG performance status 0/1 127/4, stage I/II/III 76/25/35, squamous/adenocarcinoma/large-cell/mixed histology 62/49/17/8, smokers yes/no 121/11. Positivity of p53, Bcl-2, HER-2 and Ki67 was detected in 51.4%, 27.9%, 25.0% and 55.8% of the samples, respectively; 82.9% of the cases revealed aneuploid DNA histograms and 56.7% presented an S-phase fraction of more than 12%. Statistically significant associations between high Ki67 and poorly differentiated tumors (P = 0.016) and a smoking history (P = 0.053); p53 positivity and high Ki67 (P = 0.002); HER-2 positivity and adenocarcinoma subtype (P = 0.015) and presence of lymph node involvement (P = 0.006); and Bcl-2 positivity and squamous cell carcinoma subtype (P= 0.058) were observed. At univariate analysis, high Ki67 proved to be the only marker associated with disease-free survival (P = 0.047). After adjusting for stage, none of the examined immunocytochemical markers emerged as an independent factor for disease-free and overall survival; only pathological stage was identified as an independent prognostic factor for disease-free survival (P = 0.0001) and overall survival (P = 0.0001). In the group of 76 patients classified as TNM stage I, high Ki67 was the only marker associated with recurrence of disease (P= 0.05). Conclusions. Our data do not support a relevant prognostic role of immunocyto-chemical markers in NSCLC, even if the Ki67 index might have particular relevance to identify patients with more aggressive tumors who are at high risk for disease relapse.
KW - Bd-2
KW - DNA ploidy
KW - HER-2
KW - Ki67
KW - Non-small cell lung cancer
KW - p53
KW - Prognosis
KW - S-phase fraction
UR - http://www.scopus.com/inward/record.url?scp=48249087719&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=48249087719&partnerID=8YFLogxK
M3 - Article
C2 - 18705409
AN - SCOPUS:48249087719
VL - 94
SP - 398
EP - 405
JO - Tumori
JF - Tumori
SN - 0300-8916
IS - 3
ER -